Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of one systematic review(s)/meta-analysis(es). ^[1]
• Intravenous ferric carboxymaltose is probably superior to intravenous iron sucrose for increasing hemoglobin by 20 g/L or 10 g/L (Relative Risk 1.25, 95% Confidence Interval 1.06 to 1.46, Number Needed to Treat for Benefit = 9).
• Oral ferric maltol shows superiority over placebo for increasing hemoglobin levels (Relative Risk 73.00, 95% Confidence Interval 4.58 to 1164.36).
• Intravenous iron preparations may lead to more responders compared to oral iron (Relative Risk 1.17, 95% Confidence Interval 1.05 to 1.31, Number Needed to Treat for Benefit = 11), with fewer withdrawals due to adverse events (Relative Risk 0.39, 95% Confidence Interval 0.20 to 0.74).
• No significant differences in serious adverse events or therapy withdrawals were found between the studied intervention agents; however, the certainty of these findings is very low due to risk of bias and imprecision.
• Withdrawals due to adverse events may be greater with oral iron preparations compared to intravenous iron (15/554 vs. 31/373, Relative Risk 0.39, 95% Confidence Interval 0.20 to 0.74, low-certainty).
• There is no population types or subgroups information available in the reviewed studies.